Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRZ/m^2 · 1 trial · 1 indication
Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR.
| Arm | Type | Description |
|---|---|---|
| MRZ 0.5 mg/m^2 | EXPERIMENTAL | Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles |
| Name | Type | Description |
|---|---|---|
| MRZ 0.5 mg/m^2 | DRUG | NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle |
Inclusion Criteria: Prior to Amendment 13: * Age 18 years. * Karnofsky Performance Status (KPS) score 70%. * All patients must have histologic evidence of multiple myeloma. Evidence of relapsed or relapsed/refractory disease for which no other approved treatment is available and clinically indicate...
Top 20 of 25 competitors
MRZ, also known as marizomib, is an investigational small molecule being studied for the treatment of malignant glioma, multiple myeloma, and glioblastoma. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development for these oncology indications.
MRZ is a small molecule that targets the proteasome, an enzyme complex that degrades proteins. By inhibiting the proteasome, MRZ disrupts protein homeostasis in cancer cells, leading to cell death. This mechanism is being explored in clinical trials for multiple myeloma and brain cancers.
MRZ is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The drug is currently in Phase 1 clinical trials for the treatment of malignant glioma, multiple myeloma, and glioblastoma.
MRZ is currently in Phase 1 clinical development. It has completed one Phase 1 trial and one Phase 2 trial, but the most advanced ongoing development is Phase 1. MRZ is investigational and has not been approved by the FDA for any indication.
MRZ has been studied in three clinical trials. NCT00461045 was a Phase 2 trial in relapsed or relapsed/refractory multiple myeloma. NCT02330562 was a Phase 1 trial of marizomib with or without bevacizumab in glioblastoma. NCT02903069 was a Phase 1 trial of marizomib with temozolomide and radiotherapy in newly diagnosed brain cancer.
Yes, MRZ is also known as marizomib. Clinical trials listed under the name marizomib, such as NCT02330562 and NCT02903069, are studying the same drug. Marizomib is the generic name, while MRZ is a shorthand designation used in research contexts.